Trauma Flashcards (new)
Q1: What are some considerations for the induction dose of propofol in hemodynamically unstable patients?
A1: For hemodynamically unstable patients, the induction dose of propofol should be greatly decreased, with some authors suggesting a dose that is one-tenth to one-half of the normal induction dose.
Q2: What are the benefits of using ketamine for RSI in trauma patients?
A2: Ketamine is beneficial for RSI in trauma patients, especially those who are hemodynamically unstable, as it increases cardiovascular stimulation through centrally mediated sympathetic tone and catecholamine release without causing significant increases in intracranial pressure (ICP).
Q3: What is apneic oxygenation and how is it typically administered?
A3: Apneic oxygenation is the concept of pulmonary ventilation using high-flow oxygen to reduce the risk of gastric distension and pulmonary aspiration. It is typically administered using a nasal cannula with high flows (>15 L/min) during laryngoscopy and intubation.
Q4: What are the main agents used for RSI in hemodynamically unstable trauma patients?
A4: The main agents used for RSI in hemodynamically unstable trauma patients are ketamine, etomidate, and propofol at reduced doses.
Q5: What should be the next step if intubation is unsuccessful after three attempts during RSI?
A5: If intubation is unsuccessful after three attempts, the next step should be to use an airway adjunct to support oxygenation, such as a bag mask or a second-generation supraglottic airway device. If these are unsuccessful, a surgical airway should be considered.
Q6: What is the preferred muscle relaxant for RSI and what is its dose?
A6: The preferred muscle relaxant for RSI is succinylcholine, administered at a dose of 1.5 mg/kg.
Q7: What is the SSCOR DuCanto suction device used for, and what is its design feature?
A7: The SSCOR DuCanto suction device is used for airway decontamination, and it features a large-bore opening and a hyperangulated design to suction large particles and fluids effectively.
Q8: What technique is recommended for airway decontamination in the prehospital and emergency room environments?
A8: The suction assisted laryngoscopy airway decontamination (SALAD) technique is recommended for airway decontamination in the prehospital and emergency room environments.
What percentage of intubated trauma patients experience hypoxemia and develop ARDS?
In one study of 621 intubated trauma patients, 64% experienced hypoxemia, and 46% of these hypoxemic patients developed ARDS confirmed by chest radiography.
Q2: What is the pathological mechanism behind ARDS?
A2: ARDS is caused by protein-rich fluid leaving the pulmonary capillaries and accumulating within the alveoli, compounded by embolic events, surfactant dysfunction, and the development of a hyaline membrane that prevents adequate gas exchange.
Q3: What ventilation strategy is recommended for ARDS patients?
A3: Patients with ARDS should be managed with low tidal volume ventilation, plateau pressures less than 30 cm H2O, permissive hypercapnia, conservative fluid strategies, and prone positioning.
Q4: What are the management techniques for ARDS besides reduced tidal volume ventilation?
A4: Other management techniques for ARDS include the use of neuromuscular blockers to reduce mortality, and considering extracorporeal membrane oxygenation for those unresponsive to standard therapies.
Q5: What is the leading cause of early and late mortality after trauma?
A5: Hemorrhagic shock is the leading cause of early and late mortality after trauma.
Q6: How does the body initially compensate for hemorrhagic shock?
A6: The body initially compensates for hemorrhagic shock by shunting blood from low metabolic tissues to highly metabolic tissues, increasing vascular tone and systemic vascular resistance.
Q7: What is the basis for the “golden hour” in trauma care?
A7: The “golden hour” is based on data from young, healthy males in military service during the Vietnam War, indicating that selected patients will likely survive hemorrhagic shock if perfusion is restored within the first 60 minutes after traumatic injury.
Q8: What occurs during Stage II (progressive shock) of hemorrhagic shock?
A8: During Stage II (progressive shock) of hemorrhagic shock, components of the cardiovascular system start to deteriorate, including cardiac depression, vasomotor failure, thrombosis of small vessels, increased capillary permeability, and generalized cellular degeneration.
Q9: How does the administration of fluids potentially worsen the clinical state in ongoing or massive injury?
A9: The administration of fluids may worsen the clinical state in ongoing or massive injury by increasing blood pressure, which can cause more bleeding and disrupt blood clot formation.
Q10: What is the dosage and timing of tranexamic acid (TXA) for trauma patients?
A10: Tranexamic acid (TXA) is recommended to be given within 3 hours of initial injury, with a dosage of 1 g IV over 10 minutes followed by 1 g IV over 8 hours.
Q11: What are the three stages of shock?
A11: The three stages of shock are non-progressive (compensated) shock, progressive shock, and irreversible shock.
Q1: What are the four primary causes of trauma-induced coagulopathy?
A1: The four primary causes of trauma-induced coagulopathy are dilution of factors, hypothermia/acidosis, severe TBI, and hypovolemic hemorrhagic shock.
Q2: What are the endogenous and exogenous components of trauma-induced coagulopathy?
A2: Endogenous acute traumatic coagulopathy is associated with shock and hypoperfusion, while exogenous coagulopathy arises from the effects of dilution due to fluid resuscitation and consumption through bleeding and loss of coagulation factors.
Q3: How does massive resuscitation affect coagulation factors?
A3: Massive resuscitation often requires the administration of crystalloids, which dilute coagulation factors and platelets, leading to an inadequate clot and nonsurgical bleeding.
Q4: What is recommended to maintain an INR of 1.5 or less and a platelet count above 50,000 in trauma patients?
A4: The consensus statement recommends administering procoagulant products, such as plasma, cryoprecipitate, and platelets, to maintain an INR of 1.5 or less and a platelet count above 50,000.
Q5: What is the clinical effect of hypothermia on clot formation?
A5: Hypothermia primarily inhibits the initiation phase of thrombin generation and inhibits fibrinogen synthesis, resulting in a slowly formed and fragile clot that is unable to inhibit bleeding.